GOBIOM is the world’s largest manually curated database of validated and putative biomarkers, providing a comprehensive overview of the biomarker-disease relationship. Integrated with information encompassing the exploratory, preclinical and clinical domains, the database provides critical insights into diagnosis, prognosis, treatment response, safety, efficacy and toxicity. As a one-stop source for biomarker intelligence, GOBIOM enables informed clinical and therapeutic decision making to accelerate drug development.

Creating a knowledge-base from diverse sources

The GOBIOM database is meticulously curated by our scalable team of scientific experts who excerpt, enhance, and enrich biomarker data from various sources into a cutting-edge curation application. A variety of biomarker datasets encompassing experimental, pre-clinical, clinical, pharmacological and non-pharmacological, and treatment outcomes is captured using controlled vocabulary and ontologies. Following a stringent QC/QA review process the data is integrated into the end-user platform.

GOBIOM is built upon a proprietary ‘tetrahedron data-model’ that links biomarker, indication, drug, target and study population to simplify data analysis. As a relational database GOBIOM provides evidence on all possible biomarker utilities, thereby enabling the selection of right biomarkers for your research.

GOBIOM Data Coverage and Sources

- **159347** Biomarkers
- **13798** Drugs
- **3983** Indications
- **486361** Utilities
- **23429** Endpoints
- **1912** Methodologies

**Data coverage**

**Data sources**

- Pubmed database
- Clinical trial registries
- Approved assays from 510K and PMA database
- Patents
- Scientific conferences
- FDMA/EMEA/PMDA approved documents

**GOBIOM Data Curation Process**

**Proprietary techno-manual curation model**

The GOBIOM database is meticulously curated by our scalable team of scientific experts who excerpt, enhance, and enrich biomarker data from various sources into a cutting-edge curation application. A variety of biomarker datasets encompassing experimental, pre-clinical, clinical, pharmacological and non-pharmacological, and treatment outcomes is captured using controlled vocabulary and ontologies. Following a stringent QC/QA review process the data is integrated into the end-user platform.

GOBIOM is built upon a proprietary ‘tetrahedron data-model’ that links biomarker, indication, drug, target and study population to simplify data analysis. As a relational database GOBIOM provides evidence on all possible biomarker utilities, thereby enabling the selection of right biomarkers for your research.

**Biomarker**

- Assay methodology
- Companion diagnostics
- Analytical validation
- Clinical and pre-clinical validation

**Disease**

- Indication
- Disease subtypes stage, grade etc.
- Study population
- End points

**Drug**

- Dose
- Treatment duration
- Biomarker correlation with end points
- Drug-induced organ toxicities

**Target**

- Target details
- Pathways

**Nature**

- Utilities
- Statistical correlations
- Regulatory approvals
GOBIOM Applications in Drug Development

Powering an array of versatile applications

- Intuitive search mechanism
- User-friendly interface
- Flexible export options
- Insightful data visualizations
- Analytics tools & report generation
- Micro service architecture

GOBIOM Features

- Informative, Intuitive, Intelligent

GOBIOM Applications in Drug Development

Target identification
Safety/toxicity profiling
Clinical trial insights
Clinical decision support
Drug repositioning
Competitive intelligence

Our Clients

Pharmaceuticals
Biotech
Research and Academia
AI/ML Driven Drug Discovery Companies
Contract Research Organizations

For more information, visit https://www.gobiomdbplus.com/

About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients, including 15 of the top 20 large Pharma companies.

marketing@excelra.com
www.excelra.com